Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HEMISPHERX BIOPHARMA, INC

SummaryChartsNewsRatingsCalendarCompany 
 SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about HEMISPHERX BIOPHARMA, INC
09/21AIM Immunotech Inc. Announces Retirement of Ellen Lintal as Chief Financial Officer, Ef..
CI
09/21AIM IMMUNOTECH : FDA Meeting Request for Ampligen Study Transferred to Neurology Division;..
MT
09/21AIM IMMUNOTECH : Announces Positive Progress on Requested FDA Meeting for Proposed Amplige..
AQ
09/21AIM Immunotech Announces Positive Progress on Requested FDA Meeting for Proposed Amplig..
CI
09/20AIM IMMUNOTECH : Provides an Update on Its Pending Phase 2a Human Challenge Trial Using it..
AQ
09/20AIM ImmunoTech Inc. Provides Status Update on its Pending Phase 2A Human Challenge Tria..
CI
09/17AIM IMMUNOTECH : Company Presentation - September 2021
PU
09/08AIM IMMUNOTECH : Files Pre-Investigational New-Drug Application for Therapy to Treat Post ..
MT
09/08AIM IMMUNOTECH : Submits Pre-IND Application to the FDA for Phase 2 Clinical Study of Ampl..
AQ
09/08AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Study of Amp..
CI
08/25AIM IMMUNOTECH : Seeks Provisional Patent for Investigational Intranasal, Intravenous Ther..
MT
08/25AIM IMMUNOTECH : Announces Filing of Provisional Patent Application for Use of Ampligen as..
AQ
08/25AIM ImmunoTech Announces Filing of Provisional Patent Application for Use of Ampligen a..
CI
08/17AIM IMMUNOTECH : CEO Thomas K. Equels Named to Board of Directors of BioFlorida Inc
AQ
08/17AIM IMMUNOTECH : Provides Second Quarter 2021 Business Update
AQ
More most relevant news
All news about HEMISPHERX BIOPHARMA, INC
09/21AIM IMMUNOTECH INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/21AIM Immunotech Inc. Announces Retirement of Ellen Lintal as Chief Financial Officer, Ef..
CI
09/21AIM IMMUNOTECH : FDA Meeting Request for Ampligen Study Transferred to Neurology Division;..
MT
09/21AIM IMMUNOTECH : Announces Positive Progress on Requested FDA Meeting for Proposed Amplige..
AQ
09/21AIM Immunotech Announces Positive Progress on Requested FDA Meeting for Proposed Amplig..
CI
09/20AIM IMMUNOTECH : Provides an Update on Its Pending Phase 2a Human Challenge Trial Using it..
AQ
09/20AIM ImmunoTech Inc. Provides Status Update on its Pending Phase 2A Human Challenge Tria..
CI
09/17AIM IMMUNOTECH : Company Presentation - September 2021
PU
09/17AIM IMMUNOTECH INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
AQ
09/08AIM IMMUNOTECH : Files Pre-Investigational New-Drug Application for Therapy to Treat Post ..
MT
More news
News in other languages on HEMISPHERX BIOPHARMA, INC
09/21AIM IMMUNOTECH : la demande de réunion de la FDA pour l'étude sur Ampligen est transférée ..
09/08AIM ImmunoTech dépose une demande d'autorisation de mise sur le marché d'un nouveau méd..
More news
Press releases
09/21AIM IMMUNOTECH INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/21AIM IMMUNOTECH : Announces Positive Progress on Requested FDA Meeting for Proposed Amplige..
AQ
09/20AIM IMMUNOTECH : Provides an Update on Its Pending Phase 2a Human Challenge Trial Using it..
AQ
09/17AIM IMMUNOTECH : Company Presentation - September 2021
PU
09/17AIM IMMUNOTECH INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
AQ
More press releases
Upcoming event on HEMISPHERX BIOPHARMA, INC